NEWSROOM | Galderma

Nestlé enters into exclusive negotiations to sell Nestlé Skin Health to a consortium led by EQT and ADIA

A Decade of Dysport®: Galderma Celebrates 10 Years Since FDA Approval of Dysport in the U.S.

Galderma marks Rosacea Awareness Month with new insights into why some patients are self-treating and launches social media campaign to reinforce hidden impact of the disease

Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines

Nestlé Skin Health SHIELD Hosts Skin Microbiome Summit

Galderma Announces U.S. Collaboration with Nespresso®

Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session

Galderma Announces Publication of Pivotal Phase 3 PERFECT 1 and PERFECT 2 Clinical Trials of Trifarotene in Patients with Moderate Facial and Truncal Acne in the Journal of the American Academy of Dermatology

Galderma: New data reveals benefits of combining oral and topical treatment in patients with severe papulopustular rosacea

Galderma Announces Formation of Women in Aesthetics Leadership Council

Nestlé Skin Health Opens Office in Malaysia

Galderma Announces New Collaborations with Top Aesthetic Professional Skincare Brands